Michael A. Choti, MD, MBA, Banner MD Anderson, cochaired the second annual Advancing Value-Based Oncology Care meeting and shared insights into the goals of this year's event and value-based medicine as a whole.
On June 20, 2024, Michael A. Choti, MD, MBA, Banner MD Anderson, co-chaired the second annual Advancing Value-Based Oncology Care meeting in Phoenix, Arizona. In an interview with The American Journal of Managed Care®, Choti touched upon the goals of this year’s event, as well as some of the crucial challenges and considerations of value-based oncology care.
This transcript has been lightly edited
Transcript
How would you characterize the goals of, or biggest takeaways from, this second annual Advancing Value-Based Oncology Care event?
Oncology is challenging. It's expensive, it requires integration. I think a message here that we've learned is really the importance of the complexity of [value-based care], of managing cancer care in an integrated way, controlling costs. So, this meeting really highlighted how others are doing it. At Banner MD Anderson, we're an organization that's clearly moving in that direction; we showcased the direction that we're going in in this space, and I think it really made for a very exciting symposium again this year.
In your opinion, what are the most critical components that need to be in place for value-based oncology care to be successfully implemented?
The critical components to move toward value-based care, as you've heard in this conference as well, is really the creation of integrated multidisciplinary cancer management; informatics and good analytics in order to really understand cost, utilization, best practice; as well as opportunities to address disparities and care for everyone.
How can health care systems balance the cost of innovative cancer treatments with the principles of value-based care?
I think one of the challenges of cancer care is really balancing the cost of cancer care with the principles of value-based medicine. This is a challenge. How can we address this, and what are the ways we can? I think one is to leverage technologies: predictive analytics, information technology. Artificial intelligence, I think this will be an area that will support the direction of providing high-quality cancer care in the context of value-based care.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More